



THE UNIVERSITY  
*of* ADELAIDE

**Investigation of the Role and  
Mechanism of Beta-Catenin Activation  
in Acute Myeloid Leukaemia**

**Teresa Sadras**  
**B. Sc. Mol. Biol. (Hons)**

*A thesis submitted for the degree of Doctor of Philosophy in the  
School of Molecular and Biomedical Science at the University of  
Adelaide*

JUNE 2013

## **Declaration**

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution, and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I also certify that no part of this work will in the future be used in a submission for any other degree or diploma in any university or other tertiary institution without prior approval of the University of Adelaide.

I give consent to this copy of my thesis being made available for loan and photocopying, when deposited in the University Library, subject to the provision of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web via the University's digital research repository, the Library catalogue and also through web search engines.

Teresa Sadras

June 2013

## **Acknowledgments**

I would firstly like to thank my supervisors, Richard D'Andrea, Michelle Perugini and Hayley Ramshaw, for their scientific advice and support. I have been very fortunate to have three patient supervisors which have provided me with continuous guidance and encouragement throughout my PhD.

I would also like to express gratitude the University of Adelaide and the Robinson Institute for their financial support and resources.

Thank you to all of the members of the Acute Leukaemia laboratory, with whom I have worked closely with for the last four years. I am very grateful for your scientific (and non-scientific) rapport, and most of all, your friendships. You have helped make my PhD a priceless educational and personal experience. Thanks also to all the other staff and students at the Centre for Cancer Biology where this research was undertaken for making work feel like home.

To my close friends and housemates, thank you for being there throughout my PhD and reminding me that there is a life outside of the laboratory. Your support, understanding and friendships have made a large difference to my experience.

Thank you also to Federico. I am incredibly grateful for your unwavering encouragement and support. Thank you for always believing in me.

Last but not least, I would like to thank my parents and brother. You have given me more support and encouragement than I could have hoped to ask for. I could not have gotten to this point without your help, patience, support and encouragement. There are not enough words to show how much I appreciate all that you have done for me, but, thank you.

## Abbreviations

AML	Acute myeloid leukaemia
AML-ETO	AML1-Eight-Twenty One oncoprotein fusion
APC	Adenomatous polyposis coli
$\beta$ c	Common beta-subunit
BCL-2	B-cell lymphoma 2
BM	Bone marrow
ChIP	Chromatin immunoprecipitation
ChEA	ChIP enrichment analysis
GSEA	Gene set enrichment analysis
CISH	Cytokine-inducible SH2-containing protein
CK1 $\alpha$	Casein kinase 1 alpha
CML	Chronic myeloid leukaemia
CSC	Cancer stem cell
CSF2RB	Colony stimulating factor 2 receptor beta
EGR-1	Early growth response protein 1
ERK	Extracellular regulated kinase
FAB	French-American-British
FACS	Fluorescence activated cell sorting
FCS	Foetal calf serum
FDM	Factor-dependent myeloid
FDR	False discovery rate
FRA-1	Fos-related antigen 1
GFP	Green fluorescent protein
GSK3 $\beta$	Glycogen synthase kinase 3 beta
GM	Granulocyte-macrophage
GM-CSF	Granulocyte-macrophage colony stimulating factor
GMP	Granulocyte-macrophage progenitor

HSC	Haematopoietic stem cell
HOX	Homeobox
IL-3	Interleukin-3
IL-3R	Interleukin-3 receptor
IL-3R $\alpha$	Interleukin-3 receptor alpha-subunit
IL-5	Interleukin-5
ITD	Internal tandem duplication
JAK	Janus kinase
LEF	Lymphoid enhancer factor
LIMMA	Linear models for microarray data analysis
LSC	Leukaemic stem cell
mAb	Monoclonal antibody
MIG	MSCV-IRES-GFP
MLL	Mixed-lineage leukaemia
miR	Micro RNA
MSigDB	Molecular signatures database
PI3K	Phosphoinositol 3 kinase
PIM1	Proviral integration site for Moloney-murine leukaemia virus 1
PML-RAR $\alpha$	Promyelocytic leukaemia-retinoid acid receptor alpha
PTGS2	Prostaglandin-endoperoxide synthase 2
QRT-PCR	Quantitative real-time polymerase chain reaction
RUNX1	Runt-related transcription factor 1
STAT	Signal transducer and activator of transcription
TCF	T-cell factor
WHO	World Health Organization
Wnt	Wingless-type
WT	Wild-type

## Abstract

Aberrant activation of  $\beta$ -catenin is a common event in Acute Myeloid Leukaemia (AML), and accumulating evidence indicates this pathway plays a critical role in the establishment and maintenance of myeloid neoplasms. In AML, increased  $\beta$ -catenin signalling has been associated with activating mutations in the FLT3 receptor, and the oncogenic AML1-ETO and PML-RAR $\alpha$  translocation products. In the absence of these lesions, however, it remains unclear which mechanisms may activate  $\beta$ -catenin in AML more broadly. Here we have explored a potential role for the multipotent haematopoietic cytokine, interleukin-3 (IL-3) in the regulation of  $\beta$ -catenin signalling in myeloid and leukaemic cells.

We show that IL-3 can induce the dose dependent stabilisation of  $\beta$ -catenin in a myeloid model of Hox oncogenesis, and that  $\beta$ -catenin is required for IL-3 driven colony formation and growth. Enforced expression of  $\beta$ -catenin in this system allows cell survival at sub-optimal concentrations of IL-3 which may contribute to leukaemic transformation by providing a survival advantage to blast cells in the haematopoietic niche.

We also demonstrate that IL-3 can promote  $\beta$ -catenin activation in the IL-3 dependent human erythroleukaemia cell line, TF-1.8, and in primary AML cells. Furthermore, Affymetrix gene expression analysis of bone marrow cells from four AML patients treated  $\pm$  IL-3 revealed a strong correlation between the IL-3 induced signature and Wnt/ $\beta$ -catenin gene networks. Interestingly, the IL-3 receptor alpha subunit (IL-3R $\alpha$ ) has been previously shown to be overexpressed in AML leukaemic stem cells and progenitors compared to normal counterparts, and elevated levels of IL-3R $\alpha$  are associated with poor prognosis and overall survival.

Consistent with the regulation of  $\beta$ -catenin by IL-3, we show that a neutralising monoclonal antibody (7G3) which targets IL-3R $\alpha$ , inhibits IL-3 mediated activation of  $\beta$ -catenin in TF-1.8 and primary AML cells. Modified versions of 7G3 are currently undergoing clinical trials for patients with AML, and our data indicates that this therapy may be more effective for patients with elevated levels of oncogenic  $\beta$ -catenin.

As previous studies have demonstrated that cytokines can induce the inhibitory phosphorylation of GSK3 $\beta$  via activation of the PI3K/AKT pathway, we have also made use of pharmacological PI3K and AKT small molecule inhibitors to determine the importance of this axis in the IL-3 mediated regulation of  $\beta$ -catenin.

On the whole, the work in this thesis reveals a novel mechanism which may contribute to  $\beta$ -catenin activation in AML, and provides further insight into the amplitude of IL-3 signalling in normal and malignant haematopoiesis.

# Table of Contents

## CHAPTER 1 - Introduction

<b>1.1 Haematopoiesis.....</b>	<b>1</b>
<b>1.2 Acute myeloid leukaemia .....</b>	<b>3</b>
1.2.1 The molecular pathology of AML .....	4
1.2.3 The leukaemic stem cell .....	10
1.2.3.1 Characterisation of the LSC phenotype .....	12
<b>1.3 The Wnt/<math>\beta</math>-catenin pathway in Cancer and Haematological malignancies.....</b>	<b>15</b>
1.3.1 Molecular regulation of the canonical Wnt/ $\beta$ -catenin pathway .....	16
1.3.2 Activation of $\beta$ -catenin in cancer .....	18
1.3.2.1 $\beta$ -catenin in normal and malignant haematopoiesis .....	20
1.3.2.2 $\beta$ -catenin activation in AML .....	23
1.3.2.3 $\beta$ -catenin activation in CML and other leukaemias .....	25
1.3.3 How does $\beta$ -catenin signalling contribute to leukaemogenesis? .....	28
1.3.3.1 Activation of pro-proliferative target genes.....	28
1.3.3.2 Maintenance of the leukaemic stem cell population: signalling within the haematopoietic niche .....	30
<b>1.4 Molecular regulation of <math>\beta</math>-catenin stabilisation in AML: a potential link with IL-3 signalling .....</b>	<b>32</b>
1.4.1 IL-3 receptor biology, signalling and role in AML pathogenesis.....	33
<b>1.5. Project overview and aims .....</b>	<b>37</b>

## CHAPTER 2 - Materials and Methods

<b>2.1 Cell culture protocols.....</b>	<b>39</b>
2.1.1 Culture medium and supplements.....	39
2.1.2 Cell lines and AML patient samples .....	39
2.1.3 Production of retrovirus and transduction of haematopoietic cells.....	40
<b>2.2 Bacterial techniques.....</b>	<b>40</b>
2.2.1 Media and Solutions .....	40
2.2.2 Midi-prep Plasmid Purification.....	41
<b>2.3 Pharmacological inhibitor and 7G3 Assays.....</b>	<b>41</b>
2.3.1 Pharmacological inhibition of PI3K/AKT .....	41
2.3.2 Treatment of leukaemic cells with 7G3 .....	41
<b>2.4 Western immunoblotting .....</b>	<b>42</b>



2.4.1 Isolation of protein from cell lines and primary AML samples.....	42
2.4.2 SDS-PAGE gel and western blotting.....	42
<b>2.5 Cellular assays.....</b>	<b>43</b>
2.5.1 Cell Growth Assay.....	43
2.5.2 Colony formation.....	43
2.5.3 H3 Thymidine incorporation assay.....	44
2.5.4 Cell Viability analysis.....	44
2.5.5 Cell-cycle analysis.....	44
2.5.6 Morphology.....	44
2.5.7 Surface marker expression.....	45
2.5.7.1 Differentiation marker analysis of FDM cell lines.....	45
2.5.7.2 IL-3R surface expression analysis of primary AML cells.....	45
<b>2.6 Immunofluorescence staining.....</b>	<b>46</b>
<b>2.7 Quantitative Real-time PCR (QRT-PCR).....</b>	<b>46</b>
<b>2.8 Microarray Analysis of Primary AML patient samples.....</b>	<b>47</b>
<b>2.9 Statistical Analysis and Presentation of Data.....</b>	<b>49</b>

### **CHAPTER 3 - IL-3 Mediated Regulation of $\beta$ -catenin in Myeloid and Leukaemic Cell Lines**

<b>3.1 Introduction.....</b>	<b>50</b>
<b>3.2 Results.....</b>	<b>53</b>
3.2.1 $\beta$ -catenin is stabilised and activated by IL-3 signalling in FDM myeloid cells... 53	
3.2.2 Modulation of $\beta$ -catenin levels in FDM cells influences IL-3 mediated growth and survival signals..... 58	
3.2.2.1 $\beta$ -catenin is required for IL-3 driven colony formation and growth..... 58	
3.2.2.2 Ectopic expression of $\beta$ -catenin promotes survival at low concentrations of IL-3..... 64	
3.2.3 IL-3 regulates $\beta$ -catenin protein levels, nuclear localisation and transcriptional activation in leukaemic TF-1.8 cells..... 71	
<b>3.3 Discussion.....</b>	<b>75</b>

### **CHAPTER 4 - Dissecting the Signalling and Global Gene Expression Changes Induced by IL-3 in Primary AML Cells**

<b>4.1 Introduction.....</b>	<b>81</b>
<b>4.2 Results.....</b>	<b>85</b>
4.2.1 $\beta$ -catenin is stabilised by IL-3 in primary AML cells..... 85	

4.2.2 Microarray analysis of global changes in gene expression induced by IL-3 in primary AML cells.....	93
4.2.2.1 IL-3 induces a range of transcriptional changes in AML cells at 6 and 16h.	94
4.2.2.2 Stimulation of primary AML cells with IL-3 induces the activation of $\beta$ -catenin and Tcf4 transcriptional signatures .....	103
4.2.2.3 Regulation of RNA modification pathways and miRNAs by IL-3 in AML cells .....	110
<b>4.3 Discussion .....</b>	<b>116</b>
 <b>CHAPTER 5 - Final Discussion</b>	
<b>5.1 Final discussion .....</b>	<b>121</b>
<b>5.2 Summary .....</b>	<b>128</b>
 <b>REFERENCES.....</b>	 <b>129</b>
 <b>APPENDICES.....</b>	 <b>145</b>

## List of Figures

<b>Figure 1.1</b> Haematopoiesis.....	2
<b>Figure 1.2</b> Differing initiating events & target cells in the generation of leukaemic stem cells.....	13
<b>Figure 1.3</b> The canonical Wnt/ $\beta$ -catenin signalling pathway.....	17
<b>Figure 1.4</b> Intracellular signal transduction pathways activated by IL-3.....	36
<b>Figure 3.1</b> Modulation of $\beta$ -catenin levels by IL-3.....	55
<b>Figure 3.2</b> IL-3 mediated regulation of AKT and GSK3 $\beta$ phosphorylation in FDM cells.....	57
<b>Figure 3.3</b> IL-3 regulates $\beta$ -catenin through AKT-specific phosphorylation of $\beta$ -catenin at Ser552.....	59
<b>Figure 3.4</b> Ablation of $\beta$ -catenin in IL-3 dependent FDM cells derived from $\beta$ -catenin flox/flox mice.....	61
<b>Figure 3.5</b> Surface antigen expression and morphology of FDM cells with deleted $\beta$ -catenin.....	63
<b>Figure 3.6</b> Constitutive activation of $\beta$ -catenin lowers the dependency on IL-3 for cell survival.....	65
<b>Figure 3.7</b> $\beta$ -catenin modulates Bcl-2 mRNA expression in FDM cells.....	68
<b>Figure 3.8</b> Regulation of Bcl-2 expression by $\beta$ -catenin is dependent on IL-3.....	69
<b>Figure 3.9</b> IL-3 promotes $\beta$ -catenin stabilisation in TF-1.8 leukaemic cells.....	72
<b>Figure 3.10</b> IL-3 promotes $\beta$ -catenin nuclear localisation in TF-1.8 leukaemic cells.....	74
<b>Figure 3.11</b> IL-3 regulates mRNA expression of $\beta$ -catenin target genes in TF-1.8 cells.....	76
<b>Figure 4.1</b> IL-3 regulates $\beta$ -catenin levels in primary AML cells.....	87
<b>Figure 4.2</b> 7G3 inhibits IL-3 mediated phosphorylation of STAT5A/B in primary AML cells.....	88
<b>Figure 4.3</b> 7G3 inhibits IL-3 mediated stabilisation of $\beta$ -catenin in primary AML cells.....	89
<b>Figure 4.4</b> IL-3R surface expression of AML patient samples 1-4.....	91
<b>Figure 4.5</b> In vitro proliferation of AML patient samples 1-4 in response to IL-3.....	92
<b>Figure 4.6</b> Highest ranking genes induced by IL-3 in primary AML cells after 6h stimulation.....	95
<b>Figure 4.7</b> Highest ranking genes induced by IL-3 in primary AML cells after 16h stimulation.....	96
<b>Figure 4.8</b> Classification of highest ranking early, sustained and late IL-3 induced genes in primary AML cells.....	98
<b>Figure 4.9</b> Validation of PIM1 and CISH mRNA expression in primary AML samples treated with hIL-3.....	100
<b>Figure 4.10</b> Enrichment plots of proliferation and haematopoiesis related signatures identified by GSEA analysis of gene expression changes induced by IL-3 in primary AML cells.....	102
<b>Figure 4.11</b> Hierarchical clustering of AML patient samples analysed in microarray.....	104
<b>Figure 4.12</b> Genes modulated by IL-3 in primary AML cells show significant enrichment for Wnt and $\beta$ -catenin signatures.....	106
<b>Figure 4.13</b> Validation of $\beta$ -catenin target genes identified by ChEA analysis in primary AML samples treated with hIL-3.....	109
<b>Figure 4.14</b> Enrichment plots of RNA processing signatures identified by GSEA analysis of gene expression changes induced by IL-3 in primary AML cells.....	111
<b>Figure 4.15</b> Critical genes modulated by IL-3 in primary AML cells involved in consecutive steps of the mRNA processing pathway.....	112
<b>Figure 4.16</b> IL-3 regulates a subset of miRNAs in primary AML cells .....	115
<b>Figure 5.1</b> Wnt-independent regulation of $\beta$ -catenin by haematopoietic receptors activated by mutation or their cognate ligands.....	124

## List of Tables

<b>Table 1.1</b> The World Health Organisation (WHO) classification of AML.....	6
<b>Table 1. 2</b> AML prognostic risk stratification by cytogenetic abnormalities at diagnosis.....	7
<b>Table 2.1</b> Sequence of oligonucleotide primers used for QRT-PCR analysis of gene expression.....	48
<b>Table 4.1</b> Clinical information of AML patients utilised in study.....	85
<b>Table 4.2</b> ChEA analysis showing $\beta$ -catenin and TCF4/TCF7L2 ChIP target genes significantly enriched in primary AML cells treated with IL-3 for 6h.....	107
<b>Table 4.3</b> ChEA analysis showing $\beta$ -catenin and TCF4/TCF7L2 ChIP target genes significantly enriched in primary AML cells treated with IL-3 for 16h.....	108

## List of Appendices

<b>APPENDIX A</b> Modulation of $\beta$ -catenin levels by IL-3.....	145
<b>APPENDIX B</b> Deletion of $\beta$ -catenin sensitises FDM cells to IL-3 withdrawal.....	146
<b>APPENDIX C</b> Assessment of RNA quality with Bioanalyzer prior to microarray analysis.....	147
<b>APPENDIX D</b> Highest ranking genes induced by IL-3 in primary AML cells.....	148
<b>APPENDIX E</b> Categorisation of differential gene expression induced by IL-3 in AML1-4.....	150